60. Tenore, A. and others, 1980. Thyroidal response to peroral TSH in suckling and weaned rats. American Journal of Physiology, 238 (5), E428-430.

61. Slebodzinski, A.B. and others, 1998. Triiodothyronine (T3), insulin and characteristics of 5’-monodiodinase (5’-MD) in mare’s milk from partarition to 21 days post-partum. Reproduction Nutrition Development, 38 (3), 235–244.

62. Fujimoto, N. and others, 1997. Upregulation of the estrogen receptor by triiodothyronine in rat pituitary cell lines. Journal of Steroid Biochemistry and Molecular Biology, 61 (1–2), 79–85.

63. Koldovsky, О., 1989. Search for the role of milk borne biologically active peptides for the suckling. J Nutr, 119 (11), 1543–1551; Buts, J.P., 1998. Bioactive factors in milk, (in French.) Arch Pediatr, 5 (3), 298–306.

64. Faulkner, A., 1998. Insulin-like growth factor concentrations in milk and plasma after growth hormone treatment. Biochemical Society Transactions, 26 (4), S386; Baldini, E. and others, 1994. In vivo cytokinetic effects of recombinant human growth hormone (rhGH) in patients with advanced breast carcinoma. Journal of Biological Regulators and Homeostatic Agents, 8 (4), 113–116; Scheven, B.A. and others, 1991. Effects of recombinant human insulin-like growth factor-1 and -2 (IGF) and growth hormone (GH) on the growth of normal adult human osteoblast-like cells and human osteogenic sarcoma cells. Growth Regulation, 1 (4), 160–167; Hodate, K. and others, 1990, Plasma growth hormone, insuline-like growth factor-1, and milk production response to exogenous human growth hormone-releasing factor analogs in dairy cows. Endocrinolo-gia Japonica, 37 (2), 261–273.

65. Koldovsky, O., 1989. Search for the role of milk borne biologically active peptides for the suckling. J Nutr, 119 (11), 1543–1551; Buts, J.P., 1998. Bioactive factors in milk, (in French.) Arch Pediatr, 5 (3), 298–306.

66. Westrom, B.R. and others, 1987. Levels of immunoreactive insulin, neurotensin, and bombesin in porcine colostreum and milk. / Pediatr Gastroenterol Nutr, 6 (3), 460–465; Ehman, R. and others, 1985. Bombesin, neurotensin and pro-gamma-mel-anotropin in immunoreactants in human milk. Regulatory Peptides, 10 (2–3), 99-105.

67. Shutt, D.A. and others, 1985. Comparison of total and free cortisol in bovine serum and milk colostreum. J Dairy Set, 68 (7), 1832–1834.

68. Vaarala, O. and others, 1998. Cow milk feeding induces antibodies to insulin in children – a link: between cow milk and insulin-dependent diabetes mellitus? Scandinavian Journal of Immunology 47 (2), 131–135; Slebodzinsky, A.B. and others,

1998. Triiodothyronine (T3), insulin and characteristics of 5’-monodiodinase (5’-MD) in mare’s milk from partarition to 21

days post-partum. Reprod Nutr Dev, 38 (3), 235–244; We-strom, B.R. and others, 1987. Levels of immunoreactive insulin, neurotensin, and bombesin in porcine colostreum and milk. J Pediatr Gastroenterol Nutr, 6 (3), 460–465.

69. Ferrando, T. and others, 1990. Beta-endorphin-like and alpha-MSH-like immunoreactivities in human milk. Life Sei, 47 (7), 633–635.

70.Newcomb, P.A. and Egan, K.M., 2006. Dairy food and ovarian cancer risk. The Lancet, March 2006, 797–799; Stang, A. and others, 2006. Adolescent milk fat and galactose consumption and testicular germ cell cancer. Cancer Epidemiology and Biomarkers Prevention, 15,2189–2195.

71. Maruuchi, T. and others, 1998. Effects of gonadotropin-releasing hormone agonist on rat ovarian adenocarcinoma cell lines in vitro and in vivo .Japanese Journal of Cancer Research, 89 (9), 977–983; Kuroda, H. and others, 1998. Human chorionic gonadotrophin (hCG) inhibits cisplatin-induced apoptosis in ovarian cancer cells: possible role of up-regulation of IGF-1 by hCG. Int J Cancer, 76 (4), 571–578; Kurbacher, C.M. and others, 1995. Influence of luteinising hormone on cell growth and С A 125 secretion of primary epithelial ovarian carcinomas in vitro. Tumour Biology, 16 (6), 374–384; Manetta, A. and others, 1995. Inhibition of growth of human ovarian cancer in nude mice by luteinising hormone-releasing hormone antagonist Cetrorelix (SB-75). Fertility and Sterility, 63 (2), 282–287.

72. Reiter, E. and others, 1999. Effects of pituitary hormones on the prostate. Prostate, 38 (2), 159–165; Lamharzi, N. and others, 1998. Luteinising hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-2 in tumors. Regulatory Peptides, 77 (113), 185–192; Jungwirth, A. and others, 1997. Luteinising hormone-releasing hormone (LH-RH) antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-2 inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. Prostate, 32 (3), 164–172; Maeza-wa, H. and others, 1997. Potentiating effect of buserelin ace-t"ate, an LHRH agonist on the proliferation of ventral prostatic epithelial cells in testosterone-treated castrated rats. Int J Urol,

4 (4), 411–416; Using, АЖ and others, 1993. Serological precursors of cancer serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev, 2 (1), 27–32; Garde, S. and others, 1993. Effect of prostatic inhibiting peptide on prostate cancer cell growth in vitro and in vivo. Prostate, 7 (2), 183–194.

73. Bosland, M.C., 1996. Hormonal factors in carcinogenesis of the prostate and testis in humans and in animal models. Progress in Clinical and Biological Research, 394, 309–352.